Experimental models of Huntington's disease

被引:9
|
作者
Garcia-Ramos, R.
del Val-Fernandez, J.
Catalan-Alonso, M. J.
Barcia-Albacar, J. A.
Matias-Guiu, J.
机构
[1] Hosp Clin San Carlos, Unidad Trastornos Movimiento, E-28040 Madrid, Spain
[2] Hosp Clin San Carlos, Serv Neurocirugia, E-28040 Madrid, Spain
[3] Hosp Clin San Carlos, Inst Neurociencias, E-28040 Madrid, Spain
关键词
3-nitropropionic acid; cellular models; excitotoxic models; Huntington's disease; quinolinic acid; Transgenic mice;
D O I
10.33588/rn.4507.2007238
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Huntington's disease (HD) is an autosomal dominant hereditary disease caused by triplet repetition in exon I of the huntingtin protein located in chromosome 4. Medium spiny neurons in the striatum are selectively affected. Clinical manifestations include progressive behavioural, motor and cognitive disorders. There is no treatment available today capable of modifying the natural course of the disease. A great amount of research work is being carried out, much of which involves animal models of the disease. Development. We reviewed the articles published in PubMed on basic research into HD and analysed the most frequently used models. Transgenic mouse models, excitotoxic models, transgenic fly models and cell cultures are all used in studies into HD. The advantages and disadvantages of each of them are highlighted. Conclusion. The contribution made by each model of HD must be known in order to draw up a correct design in experimental studies of the disease. [REV NEUROL 2007; 45: 437-41]
引用
收藏
页码:437 / 441
页数:5
相关论文
共 50 条
  • [21] Minocycline in phenotypic models of Huntington's disease
    Bantubungi, K
    Schiffmann, SN
    Jacquard, C
    Brouillet, E
    Greco, A
    Minghetti, L
    Pintor, A
    Popoli, P
    Galas, MC
    Déglan, N
    Brotchi, J
    Levivier, M
    Chtarto, A
    Tai, K
    Tenenbaum, L
    Blum, D
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76
  • [22] Rodent Models of Huntington's Disease: An Overview
    Nittari, Giulio
    Roy, Proshanta
    Martinelli, Ilenia
    Bellitto, Vincenzo
    Tomassoni, Daniele
    Traini, Enea
    Tayebati, Seyed Khosrow
    Amenta, Francesco
    BIOMEDICINES, 2023, 11 (12)
  • [23] Neuroprotective Effects of Phytocannabinoid-Based Medicines in Experimental Models of Huntington's Disease
    Sagredo, Onintza
    Pazos, M. Ruth
    Satta, Valentina
    Ramos, Jose A.
    Pertwee, Roger G.
    Fernandez-Ruiz, Javier
    JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (09) : 1509 - 1518
  • [24] Meclizine is neuroprotective in models of Huntington's disease
    Gohil, Vishal M.
    Offner, Nicolas
    Walker, James A.
    Sheth, Sunil A.
    Fossale, Elisa
    Gusella, James F.
    MacDonald, Marcy E.
    Neri, Christian
    Mootha, Vamsi K.
    HUMAN MOLECULAR GENETICS, 2011, 20 (02) : 294 - 300
  • [25] Huntington's disease: Pathogenesis to animal models
    Kumar P.
    Kalonia H.
    Kumar A.
    Pharmacological Reports, 2010, 62 (1) : 1 - 14
  • [26] Plastic abnormalities in experimental Huntington's disease
    Di Filippo, Massimiliano
    Tozzi, Alessandro
    Picconi, Barbara
    Ghiglieri, Veronica
    Calabresi, Paolo
    CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (01) : 106 - 111
  • [27] Experience of experimental modelling of Huntington’s disease
    Stavrovskaya A.V.
    Voronkov D.N.
    Yamshchikova N.G.
    Ol’shanskiy A.S.
    Khudoerkov R.M.
    Illarioshkin S.N.
    Human Physiology, 2016, 42 (8) : 898 - 904
  • [28] Experimental Surgical Therapies for Huntington's Disease
    Demeestere, Jelle
    Vandenberghe, Wim
    CNS NEUROSCIENCE & THERAPEUTICS, 2011, 17 (06) : 705 - 713
  • [29] Transgenic Mouse Models of Parkinson's Disease and Huntington's Disease
    Skaper, Stephen D.
    Giusti, Pietro
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (04) : 455 - 470
  • [30] Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and Parkinsonism
    Reiter, RJ
    Cabrera, J
    Sainz, RM
    Mayo, JC
    Manchester, LC
    Tan, DX
    NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE, 1999, 890 : 471 - 485